The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Merck will encounter some Keytruda-related issues toward the end of the decade, but the company's business and pipeline are ...

Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. Receive News & Ratings for Bellerophon Therapeutics Daily - Enter ...

Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

62% of patients had intermediate-high COMPERA 2.0 risk status, whereas at follow-up, 61% were intermediate-low or low risk.

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report released on Wednesday morning. The firm issued a hold rating on the biotechnology ...

In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.

Based on their findings, the researchers suggest the integration of automated measures to identify interventricular septal ...

The woman was suffering from Eisenmenger syndrome, a condition that occurs when a congenital heart defect causes abnormal blood circulation, resulting in pulmonary hypertension and lung damage. "As ...

a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.